PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
about
Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingPredictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.PET imaging of recurrent and metastatic prostate cancer with novel tracers.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTDevelopment of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.Imaging features of Paget's disease on 11C choline PET/CT.[Focus on molecular imaging in prostate cancer].Highlights of articles published in annals of nuclear medicine 2016.Surrogate end points in early prostate cancer clinical states: ready for implementation?Current status of theranostics in prostate cancer.11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.Post-prostatectomy radiation therapy for locally recurrent prostate cancer.Improving postoperative radiotherapy following radical prostatectomy.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.[The role of PSMA PET-CT in patients with metastatic prostate cancer].The use of PET/CT in prostate cancer.[The role of PSMA PET-CT in patients with metastatic prostate cancer].Molecular imaging of prostate cancer.[Significance of PSMA imaging in prostate cancer].Impact of time-of-flight PET on quantification accuracy and lesion detection in simultaneous 18F-choline PET/MRI for prostate cancer.Interpretation of 11C-choline PET/CT for the diagnosis of local relapse in radically treated prostate cancerDiagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysisPET/MRI and prostate cancerRole of PET imaging for biochemical recurrence following primary treatment for prostate cancerClinical implications of PET/CT in prostate cancer management
P2860
Q28074669-D38D432F-66EF-4E22-9F64-6C63A552591AQ37427275-CC14C81A-E9AF-42F5-9B4C-83A7166276ECQ37707083-F1281DCA-E896-4AFF-A105-18EE5B49BF08Q38747415-4084BDEC-EB13-400A-8004-1A6BA56FBC46Q38804450-9FC4362E-DF26-405E-B9CC-A972AE807F4CQ38831029-6B1886A6-FD43-430D-99B4-7A734BCCC896Q39242140-74008F94-D6A8-4266-9BFB-B8438296B9EDQ39419798-688B468D-CC64-41B9-B73B-6494C1719052Q39699773-1A10E2C7-FE23-4000-9840-3A9AB50DB1E9Q39922053-DB5D7987-CAF4-4786-A2A9-C6FB56289577Q40188618-428E681C-C5B4-4879-A761-EEAE371B121AQ41019269-5EA33909-B866-478A-BA7B-3333EA077EDDQ41585395-EC51D696-0813-4481-B499-BCE3706F4FA2Q45970536-AEB3C438-CFEF-4F86-9F98-D58CF1C87277Q47102678-FE0009CB-1DF3-4B07-95F9-DB36A68AF18FQ47241139-25993FA1-A2BF-4833-B4F4-8FE4A234163FQ47693880-357008BC-5940-4AF4-B612-08129F64BF1BQ47829959-D9DB565E-4427-433F-B759-6DC5C448C609Q47966425-244E6D51-5811-4412-AB2D-C2C8687B7949Q47978964-55FD38B6-0FB2-49D9-8DA5-20948B4F7C3DQ48189196-48407376-7C86-4BD2-A488-4BE522BA5065Q48295687-43DF9B46-157A-4A23-8800-F900E115451AQ48316900-A03E0665-79DE-4317-8E28-6234FD21A07EQ49589359-A64BC01C-6492-4DE7-BA09-C696D5A10C40Q49919217-D3C758C6-7C8A-4F85-AFE6-530BD8E95E6BQ49981290-DF2A45EE-4FCC-46D5-8E5D-36AFCEC2F11FQ52411549-164CF188-9FF2-47EE-88C3-8C9715615853Q52937814-6AAB2D40-463A-4484-9CE2-9B7DBA0C6B2BQ55371355-61AE300F-7355-44B8-920A-A3E62D910301Q56961941-8A64CD5A-73A5-4809-9527-8864D3768249Q57106260-3AAB6436-CF0A-4490-B794-1FD1A3929430Q57780524-890B522A-7BD8-4525-A129-DB2B956727DFQ58562169-8D638446-035B-40B6-8CE3-5A0D856AB82BQ59137133-5DDDEA2B-710D-4F76-841F-B300BD241C67
P2860
PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
PET/CT with (11)C-choline for ...... ical review of available data.
@ast
PET/CT with (11)C-choline for ...... ical review of available data.
@en
type
label
PET/CT with (11)C-choline for ...... ical review of available data.
@ast
PET/CT with (11)C-choline for ...... ical review of available data.
@en
prefLabel
PET/CT with (11)C-choline for ...... ical review of available data.
@ast
PET/CT with (11)C-choline for ...... ical review of available data.
@en
P2093
P2860
P50
P1476
PET/CT with (11)C-choline for ...... ical review of available data.
@en
P2093
Bernd Joachim Krause
Ken Herrmann
Paolo Castellucci
Silvia Minozzi
P2860
P2888
P356
10.1007/S00259-015-3202-7
P577
2015-10-09T00:00:00Z
P6179
1006784750